TS-161 is under clinical development by Taisho Pharmaceutical and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TS-161’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TS-161 overview

TS-161 is under development for the treatment of major depressive disorder (MDD) and treatment resistant depression. The drug candidate is administered through oral route in the form of capsule and tablet. It acts by targeting MGLUR2 and MGLUR3.

Taisho Pharmaceutical overview

Taisho Pharmaceutical develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company’s self-medication products comprise over the counter (OTC) products, quasi-drugs and health food products. Its prescription pharmaceuticals portfolio includes ethical drugs in the fields of infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases. Taisho Pharmaceutical provide its products under Pabron, Lipovitan D, Riup, Livita, Colac, Zosyn, Clarith, Edirol, Palux, Geninax, and Lorcam brand names. The company operates through its subsidiaries located in the Philippines, Indonesia, Malaysia, Thailand, Vietnam, China, Singapore, Taiwan and the US. Taisho Pharmaceutical is headquartered in Toshima-ku, Tokyo, Japan.

For a complete picture of TS-161’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.